Shirvani M, Yadollahi A, Zamanzadeh Z, Abkar M, Yousefnia S. Association of MT1A rs11640851, rs8052394 and rs11076161 polymorphisms with the risk of developing breast cancer: a haplotype-based case-control study and in silico analysis. 2024. Preprint at: https://www.researchsquare.com/article/rs-3867462/v1.

Jaman MS, Al Mamun A, Sharker B, Maniruzzaman M, Rana MRR, Hasan MN, et al. Curcumin, Diallyl sulphide, Quercetin and Gallic acid uses as anticancer and therapeutic agents for breast cancer: current strategies and future perspectives. Eur J Med Health Sci. 2023;5(3):32–48.

Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Ca Cancer J Clin. 2023;73(1):17–48.

Article  PubMed  Google Scholar 

Rahimi G, Yousefnia S, Angnes L, Negahdary M. Design a pegylated nanocarrier containing Lemongrass essential oil (LEO), a drug delivery system: application as a cytotoxic agent against breast cancer cells. J Drug Deliv Sci Technol. 2023;80:104183.

Article  CAS  Google Scholar 

Swaminathan H, Saravanamurali K, Yadav SA. Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment. Med Oncol. 2023;40(8):238.

Article  PubMed  Google Scholar 

Singh R, kumar Sain MN. Etiology Of Breast Cancer. J Pharm Negat Results. 2023;1427–34.

Yousefnia S. Breast cancer, subtypes, risk factors, and treatment. The Palgrave Encyclopedia of Disability: Springer; 2024. pp. 1–14.

Google Scholar 

Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77–106.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park M, Kim D, Ko S, Kim A, Mo K, Yoon H. Breast cancer metastasis: mechanisms and therapeutic implications. Int J Mol Sci. 2022;23(12):6806.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yousefnia S. Association between genetic polymorphism of catalase (CAT) C-262T, Cu/Zn superoxide dismutase (SOD1) A251G and risk of age-related macular degeneration. Mol Biochem Diagnosis J. 2014;1(2):77–88.

Google Scholar 

Asadi S, Abkar M, Zamanzadeh Z, Taghipour Kamalabad S, Sedghi M, Yousefnia S. Association of SOD2 rs2758339, rs5746136 and rs2842980 polymorphisms with increased risk of breast cancer: a haplotype-based case–control study. Genes Genomics. 2023;1–14.

Rodrigo MAM, Jimemez AMJ, Haddad Y, Bodoor K, Adam P, Krizkova S, et al. Metallothionein isoforms as double agents–their roles in carcinogenesis, cancer progression and chemoresistance. Drug Resist Updates. 2020;52:100691.

Article  Google Scholar 

Juárez-Rebollar D, Rios C, Nava-Ruíz C, Méndez-Armenta M. Metallothionein in brain disorders. Oxid Med Cell Longev. 2017;2017.

Vašák M, Meloni G. Mammalian metallothionein-3: new functional and structural insights. Int J Mol Sci. 2017;18(6):1117.

Article  PubMed  PubMed Central  Google Scholar 

Giacconi R, Cai L, Costarelli L, Cardelli M, Malavolta M, Piacenza F, et al. Implications of impaired zinc homeostasis in diabetic cardiomyopathy and nephropathy. BioFactors. 2017;43(6):770–84.

Article  CAS  PubMed  Google Scholar 

Krezel A, Maret W. The bioinorganic chemistry of mammalian Metallothioneins. Chem Rev. 2021;121(23):14594–648.

Article  CAS  PubMed  Google Scholar 

Dai H, Wang L, Li L, Huang Z, Ye L. Metallothionein 1: A new spotlight on inflammatory diseases. Front Immunol. 2021;12:739918.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raudenska M, Gumulec J, Podlaha O, Sztalmachova M, Babula P, Eckschlager T, et al. Metallothionein polymorphisms in pathological processes. Metallomics. 2014;6(1):55–68.

Article  CAS  PubMed  Google Scholar 

Si M, Lang J. The roles of Metallothioneins in carcinogenesis. J Hematol Oncol. 2018;11(1):1–20.

Article  PubMed  PubMed Central  Google Scholar 

Hengstler J, Pilch H, Schmidt M, Dahlenburg H, Sagemüller J, Schiffer I, et al. Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis. Int J Cancer. 2001;95(2):121–7.

Article  CAS  PubMed  Google Scholar 

Wülfing C, van Ahlen H, Eltze E, Piechota H, Hertle L, Schmid K-W. Metallothionein in bladder cancer: correlation of overexpression with poor outcome after chemotherapy. World J Urol. 2007;25:199–205.

Article  PubMed  Google Scholar 

Gomulkiewicz A, Podhorska-Okolow M, Szulc R, Smorag Z, Wojnar A, Zabel M, et al. Correlation between Metallothionein (MT) expression and selected prognostic factors in ductal breast cancers. Folia Histochem Cytobiol. 2010;48(2):242–8.

Article  PubMed  Google Scholar 

Jayasurya A, Bay B, Yap W, Tan N, Tan B. Proliferative potential in nasopharyngeal carcinoma: correlations with Metallothionein expression and tissue zinc levels. Carcinogenesis. 2000;21(10):1809–12.

Article  CAS  PubMed  Google Scholar 

Weinlich G, Eisendle K, Hassler E, Baltaci M, Fritsch P, Zelger B. Metallothionein–overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients. Br J Cancer. 2006;94(6):835–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han YC, Zheng ZL, Zuo ZH, Yu YP, Chen R, Tseng GC, et al. Metallothionein 1 h tumour suppressor activity in prostate cancer is mediated by euchromatin methyltransferase 1. J Pathol. 2013;230(2):184–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Datta J, Majumder S, Kutay H, Motiwala T, Frankel W, Costa R, et al. Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein α by phosphatidylinositol 3-kinase signaling cascade. Cancer Res. 2007;67(6):2736–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krześlak A, Forma E, Jóźwiak P, Szymczyk A, Smolarz B, Romanowicz-Makowska H, et al. Metallothionein 2A genetic polymorphisms and risk of ductal breast cancer. Clin Experimental Med. 2014;14:107–13.

Article  Google Scholar 

Forma E, Krzeslak A, Wilkosz J, Jozwiak P, Szymczyk A, Rozanski W, et al. Metallothionein 2A genetic polymorphisms and risk of prostate cancer in a Polish population. Cancer Genet. 2012;205(9):432–5.

Article  CAS  PubMed  Google Scholar 

Rosa RR, Garcia MAJ, Alves PT, Sousa EM, Pimentel LS, de Paula Barbosa L, et al. Revisiting the metallothionein genes polymorphisms and the risk of oral squamous cell carcinoma in a Brazilian population. Med Oral, Patol Oral y Cir Bucal. 2021;26(3):e334.

Article  Google Scholar 

Wong R-H, Huang C-H, Yeh C-B, Lee H-S, Chien M-H, Yang S-F. Effects of metallothionein-1 genetic polymorphism and cigarette smoking on the development of hepatocellular carcinoma. Ann Surg Oncol. 2013;20:2088–95.

Article  PubMed  Google Scholar 

Cherian MG, Jayasurya A, Bay B-H. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Research/Fundamental Mol Mech Mutagen. 2003;533(1–2):201–9.

Article  CAS  Google Scholar 

Eckschlager T, Adam V, Hrabeta J, Figova K, Kizek R. Metallothioneins and cancer. Curr Protein Pept Sci. 2009;10(4):360–75.

Article  CAS  PubMed  Google Scholar 

Costa MI, Sarmento-Ribeiro AB, Gonçalves AC. Zinc: from biological functions to therapeutic potential. Int J Mol Sci. 2023;24(5):4822.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krizkova S, Ryvolova M, Hrabeta J, Adam V, Stiborova M, Eckschlager T, et al. Metallothioneins and zinc in cancer diagnosis and therapy. Drug Metab Rev. 2012;44(4):287–301.

Article  CAS  PubMed  Google Scholar 

Parida L, Patel TN. Systemic impact of heavy metals and their role in cancer development: a review. Environ Monit Assess. 2023;195(6):766.

Article  CAS  PubMed  Google Scholar 

Prasad S, Gupta SC, Tyagi AK. Reactive oxygen species (ROS) and cancer: role of antioxidative nutraceuticals. Cancer Lett. 2017;387:95–105.

Article  CAS  PubMed